Year-end Report 2009 Tripep AB (publ)

 Research and development costs amounted to SEK 6.4 (17.1) m  The loss after tax was SEK -11.6 (-24.9) m  Earnings per share were SEK -0.27 (-1.77)  Net sales SEK 0.4 (3.8) m  The company has carried out two private placements raising SEK 6 m before transaction costs through the placements during the summer 2009, and in December 2009 a rights offering which was fully subscribed. Through the rights offering Tripep received 17.8 MSEK before transaction costs  The ChronVac-C® study has been finalized and showed that the therapeutic vaccine is safe and gave positive clinical data. The Swedish Medical Product’s Agency and the ethical committees in December gave their approvals for giving three of the patients in the ChronVac-C® study a 5th dose. This dose is given approximately six to 12 months after the 4th vaccination in order to study possible positive effects of a so called booster-dose given after a longer time frame. Four patients who after completing the ChronVac-C® study have started treatment according to standard of care, i.e. interferon in combination with ribavirin have responded with an unusually rapid reduction of virus in the blood. This indicates a role for ChronVac-C® in combination therapy  The multi-center study on ChronSeal® is ongoing in Sweden and Norway. In an interim analysis of the treatment effect it was concluded that the group of patients randomized for placebo treatment with the new antibacterial formulation without HGF still was too small for allowing statistical analysis  Tripep has out licensed the RAS® technology to Opsonic Therapeutics  Tripep has applied for a patent for a new type of injection-needle for DNA vaccination in man. The needle is intended for use with commercially available syringes and has in animal experiments been shown to increase the effect of DNA vaccination as compared to normal injection needles Events after the end of the reporting period  Follow up of ChronVac-C® study with a 5th dose commenced For more information, please contact: Anders Vahlne, CEO and Head of Research, Tripep AB Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28, E-mail: anders.vahlne@ki.se Tripep develops the therapeutic DNA-vaccines ChronVac-C® and ChronVac-B drugs against chronic hepatitis C virus and hepatitis B-virus infections, i.e. chronic infections with jaundice causing viruses which can lead to liver cirrhosis and liver cancer. Tripep has also developed and further develops a patent pending new type of injection needle for a more effective uptake of DNA vaccines. Tripep also have part ownership in the wound healing therapy ChronSeal®, and in the new platform technology RAS®. The Tripep share is admitted to trade on First North. Remium AB is Certified Adviser for Tripep AB. For more information, please visit: www.tripep.se In the event of any discrepancy between the Swedish and English versions of this press release, the Swedish version will take precedence.